Citations

Clear

13 citation(s) found for "Bhat, Mamatha".

Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells
Bhat, Mamatha , Yanagiya, Akiko , Razumilava, Nataliya , Bronk, Steve F., Zammit, Domenick, Zhao, Yunhao, Zakaria, Chadi, Metrakos, Peter , Pollak, Michaël , Sonenberg, Nahum , Jaramillo, Maritza , Morita, Masahiro , Bronk, Steve, Graber, Tyson Ernst , Gores, Gregory J. , Alain, Tommy , Pollak, Michael N , Bhat, Mamatha

Mayo Clinic

Oncotarget | July 18, 2016 | Volume: 8 | Issue: 31 | Pages: 50542-50556

10.18632/oncotarget.10671 | PMID 28881582 Get It

Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol
Bhat, Mamatha , Hathcock, Matthew , Kremers, Walter K. , Murad, Sarwa Darwish , Schmit, Grant D. , Martenson, James A., Rosen, Charles B. , Darwish Murad, Sarwa, Schmit, Grant, Martenson, James, Alberts, Steven, Alberts, Steven R. , Gores, Gregory J. , Heimbach, Julie K. , Bhat, Mamatha , Kremers, Walter K , Darwish Murad, Sarwa

Mayo Clinic

Transplant International | July 16, 2015 | Volume: 28 | Issue: 12 | Pages: 1383-1391

10.1111/tri.12640 | PMID 26183487 Get It

Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Bhat, Mamatha , Watt, Kymberly D. , Bhat, Mamatha

Mayo Clinic

Clinical Transplantation | June 19, 2015 | Volume: 29 | Issue: 7 | Pages: 654-663

10.1111/ctr.12559 | PMID 26094583 Get It

AbstractThe mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor‐based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.